A phase 1–2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]
2006

Study on Sulfasalazine for Malignant Gliomas

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): Robe Pierre A, Martin Didier, Albert Adelin, Deprez Manuel, Chariot Alain, Bours Vincent

Primary Institution: University of Liège

Hypothesis

Sulfasalazine should be well tolerated by patients with recurrent or progressive malignant glioma and could inhibit tumor progression.

Conclusion

The study aims to evaluate the safety and efficacy of Sulfasalazine in treating malignant gliomas.

Supporting Evidence

  • Sulfasalazine has been shown to inhibit the growth of glioblastoma cells.
  • The study is designed to assess the safety and efficacy of Sulfasalazine in patients with malignant gliomas.
  • Patients will be monitored for adverse events and tumor response.

Takeaway

This study is testing a medicine called Sulfasalazine to see if it can help people with a type of brain cancer called malignant gliomas.

Methodology

A phase 1–2, single center, prospective, randomized, double blind study with 20 patients assigned to different dosages of Sulfasalazine.

Potential Biases

Potential bias in patient selection and reporting of adverse events.

Limitations

The study is limited to a small sample size and specific patient demographics.

Participant Demographics

Adult patients (age > 18) with recurrent or progressive WHO grade 3 or 4 astrocytic gliomas.

Digital Object Identifier (DOI)

10.1186/1471-2407-6-29

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication